Kornimate/medical-research-clean huggingface dataset:
systematically assessing effects of colored light on humans with a multi-modal approach (substudy 2 of 7)

Conditions: Exposure to Man-made Visible Light

Summary: note: this is the second of in total 7 sub-studies related to the ethics committee of the canton of bern ref. no. kek-be 2016-00674. this sub-study includes 50 participants and 6 arms, in total 350 participants will be assessed in all 7 sub-studies. general study information: this is a randomized, cross-over, quantitative study, which investigates physiological variables, mood, and affect of healthy participants in response to colored light exposure. the participants take part in 5-8 arms and are exposed to colored light only, or are additionally asked to solve cognitive tasks during the colored light exposure. primary aim is to measure the change in several physiological variables, mood, and affect during colored light exposure of 15 or 45 minutes. the risk for the participants is negligible and comparable to the risk during daily life.


Eligibility criteria:
inclusion criteria: * normal color vision * right handed * written informed consent exclusion criteria: * smoking * any kind of diagnosed sleep disorder or neurological or psychiatric disorder in the last 3 months * acute severe traumas * chronic diseases with the necessity for medication * use of recreational drugs * regular intake of medication that would affect the outcome measures * regular excessive alcohol use (\> 18 standard units / week) * transmeridian travel in the last month (crossed \> 1 time zone border) * night shift word during the last month

Keywords: cerebral oxygen metabolism functional near-infrared spectroscopy partial pressure of carbon dioxide heart rate variability blood pressure affect mood respiration systematic randomized cross-over study systemic physiology electro-dermal activity pulse-respiratory quotient
ms paths covid-19 questionnaire data linkage sub-study

Conditions: Multiple Sclerosis (MS)

Summary: the primary objective of this sub-study is to supplement the multiple sclerosis partners advancing technology and health solutions (ms paths) dataset with coronavirus disease 2019 (covid-19)-related health information obtained from periodic participant questionnaires administered by participating ms paths institutions.


Eligibility criteria:
key inclusion criteria: 1. be enrolled in ms paths under study 888ms001. 2. completed one or more covid-19 questionnaire at a participating ms paths institution. 3. permission for data linkage either obtained when completing a local covid-19 questionnaire or granted by waiver of informed consent from the local institutional review board (irb) or ethics committee (ec). key exclusion criteria: 1. other unspecified reasons that, in the opinion of the investigator or biogen, make the participant unsuitable for participation in the sub-study. a participant only needs to complete the assessments deemed necessary by the investigator. note: other protocol defined inclusion/exclusion criteria may apply.
evaluating the relationship between environmental risk factors in housing types and chronic respiratory diseases in ho chi minh city

Conditions: Chronic Respiratory Diseases

Summary: the research question is "are the different types of house in ho chi minh city equally contributing to chronic respiratory diseases?". according to this question, a cross-sectional and explorative study was set up to explore the differences in the environmental characteristics and prevalence of chronic respiratory diseases among common housing types in ho chi minh city. preliminary work was performed in 100 houses (20 houses per type, included tube houses, rental houses, rural houses, slum and apartment) from november 2013 to june 2015. it included measures by environmental devices, questionnaires and indoor activities diaries. this study will aim to collect information about the prevalence of chronic respiratory diseases (crds) inside those house types to understand more about role of house types in developing crds. the objective is: 1. to evaluate the relationships between the type of house and lung function of inhabitants in each housing type. 2. to evaluate the effects of environmental risk factors in each house type on prevalence of crds


Eligibility criteria:
inclusion criteria: * everybody exclusion criteria: * not able to answer the questionnaire or give informed consent * have a contra-indication for lung function test (acute myocardial infarction less that 1 month ago, pain related to spirometry, dementia/confused)

Keywords: chronic respiratory diseases housing lung function test
clinical efficacy of nail brace for treatment of ingrown toenails

Conditions: Ingrown Nail

Summary: background: ingrown toenails are one of the most frequent nail disorders and can be treated with conservative or surgical approaches. although discovered a long time ago, the available data are still very limited on the potential effectiveness of nail braces for ingrown toenail treatment. objective: this study aimed to evaluate the efficacy of nail brace (combiped and podofix) for treatment of ingrown toenails.

method: participants with ingrown toenail and \>= 12 years old with total 40 ingrown toenails were included. investigators divide patients to 3 group: (1) combiped group: participants with non-infected or mild infected ingrown nail, combiped nail brace was applied instantly.20 patients(2) combine combiped and podofix group: participants with severe paronychia with pyogenic granuloma, oral analgesics and antibiotics were prescribed first and nail brace was applied 1 week later. depends on disease condition, investigators applied 1-2 combiped nail brace. if the pyogenic granuloma is not resolved after 1 week, investigators applied podofix first for 2-4 weeks and then combiped nail brace. after the nail brace applied, participants must come back between 2-4 weeks depends on disease condition.10 patients (3) podofix group: participants who are afraid of combiped implantation, or with mild recurrence will be applied with podofix. participants come back every month for evaluation and photography. physician global assessment (0-6),patient global assessment (vas 0-10), treatment satisfaction (vas 0-10), and questionnaire were evaluated 1 month, 3 months and 6 months after the device applied. participants need to be followed for recurrence at 3rd month and 6th month after removed the nail brace.

Eligibility criteria:
inclusion criteria: * more or equal to 12 years old patient with ingrown toenail exclusion criteria: * \< 12 years old * under other nail bracing use * received partial nail resection within recent 2 months * psoriatic nail * target therapy related paronychia * received combiped or podofix previously and removed within recent 6 months
treatment to reduce vascular calcification in hemodialysis patients using vitamin k

Conditions: Vascular Calcification; Systemic and Arterial Stiffness; Complication of Hemodialysis; Deficiency of Vitamin K2

Summary: the proposed study will seek to evaluate the prevalence and the progression of vascular calcification in a cohort of maintenance hemodialysis patients in asian population. it will also evaluate the efficacy of vitamin k 2 supplementation in reducing the progression of vascular calcification in this group of patients. this will be a single-center randomized, prospective and open-label interventional clinical trial of end stage renal failure patients on hemodialysis.primary outcome will be absolute difference in coronary artery calcium (cac) score at 18-month between control and intervention arms. secondary outcomes will be to compare absolute difference in aortic valve calcification, percentage of patients with regression of coronary artery calcification of at least 10%, absolute difference in aortic and systemic arterial stiffness, mortality from any cause and major adverse cardiovascular events (mace) over the same period.


Eligibility criteria:
inclusion criteria: 1. age ≥ 45 years and less than 80 years 2. at least 12 months on hemodialysis 3. coronary artery calcium score of ≥ 30 in the baseline multislice computed tomography 4. able to give informed consent 5. life expectancy of at least18 months exclusion criteria: 1. history of thrombosis in the last 6 months except vascular access thrombosis 2. need for vitamin k antagonists therapy at baseline or in the 3 months prior to baseline 3. presence of significant gut disease (inflammatory bowel disease, short-bowel syndrome) 4. liver dysfunction 5. alcohol or drug abuse 6. presence of coronary stent or have undergone coronary artery bypass grafting 7. women who are pregnant or breast feeding, 8. those who are fearful of confined space and cannot lie still for multislice computed tomography 9. lack of safe contraceptive measures. 10. those who had parathyroid surgery done. 11. those with parathyroid hormone (pth) \> 150 pmol/l 12. patient taking multivitamins containing vitamin k 13. patient allergic to soy based products
transcranial pulse stimulation (tps) for alzheimer's disease (ad)

Conditions: Alzheimer Disease

Summary: this is a prospective open comprehensive proof-of-principle pilot study.

this is a prospective open comprehensive proof-of-principle pilot study with patients of mild to moderate alzheimer's disease who have been treated with transcranial pulse stimulation (tps)

Eligibility criteria:
inclusion criteria: * clinically stable patients with probable alzheimer's disease (diagnosis according to icd-10 criteria (f00)) * mmse ≥ 10: mild and moderate alzheimer's disease according to awmf register, s3 guidelines of dgn 038/013 and degam 035/021 * at least 3 months of stable antidementia therapy or no antidementia therapy necessary (patients need to continue their standard treatment within the clinical investigation according to the guidelines as tps is considered an additional treatment to standard therapy) * signed written informed consent * 18 years ≤ age ≤ 85 years * monthly pregnancy tests for female patients in childbearing age exclusion criteria: * non-compliance with the protocol (including cerad-plus) * pregnancy * breast-feeding women * microbubbles (contrast agents) in application area * cerebral pathology unrelated to alzheimer's disease * metallic objects in the head * neurosurgical intervention of the brain / craniotomy * cardiac disorders * history of psychiatric diseases before development of dementia * hemophilia or other blood clotting disorders * cortisone treatment up to 6 months before first treatment * other conditions implying increased risk according to the judgement of the investigator
effects of recursive self-feedback on speech production in aphasia

Conditions: Aphasia; Stroke

Summary: the goal of this clinical trial is to test the effects of recursive self-feedback procedures on spontaneous speech production in stroke survivors with impaired speech production (aphasia). the main question it aims to answer is: • to what extent can stroke survivors with aphasia use their self-feedback alone to improve their spontaneous speech production? participants will be engaged in the following activities: * they will perform language and cognitive tasks. * afterwards, they will receive treatments using tablets and headphones at no cost to them. * the experimental treatments (recursive self-feedback procedures) entails responding to prompts, listening to playbacks of their speech response and attempt to minimize/correct the errors in the next attempt. this process will be repeated multiple times per prompt. * the experimental treatments are two: an adaptive version that adapts the complexity of the treatment prompt and a non-adaptive version that does not adapt task complexity. * researchers will compare the experimental treatments to see if both have similar effects on improving spontaneous speech production.


Eligibility criteria:
inclusion criteria: * 6 months post left hemisphere stroke * aphasia due to left hemisphere stroke * dominant english speaker exclusion criteria: * speech-language deficits due to neurological insults such as parkinson's disease, neurodegenerative conditions etc. * uncorrected sensory impairments. * language comprehension impairment. * severe cognitive impairment.
cohort study investigating the association between antichlamydial antibody positivity and art outcomes in women with tfi

Conditions: Antichlamydial Antibodies; Chlamydia Trachomatis Infection; Infertility; Tubal Factor Infertility

Summary: in a prospective cohort study investigators will examine characteristics and clinical outcomes of treatment with art in women with tubal factor infertility (tfi) with regard to seropositivity to antichlamydial antibodies.

at the first day of stimulation blood analyses for immunoglobulin g (igg), immunoglobulin a (iga) and immunoglobulin m (igm) to major chlamydial antigens (anti-c.trachomatis), major outer membrane protein (momp) and plasmid-encoded protein (pgp3) will be performed for patients found eligible for the study. according to the result of chlamydial antibody test (cat) participants will be divided into two groups: group a - women with at least one of antibodies detected (cat+); group b - seronegative subjects (cat-). women of both groups will undergo a conventional ovarian stimulation (cos) with gnrh antagonist and daily gonadotropin administration at the dose of 150-300 international unit (iu). retrieved oocytes following fertilization (conventional ivf or icsi) will be cultured to day 3-5 in vitro; ultrasound guided single or double embryo transfer will be performed; remaining embryos of eligible quality will be vitrified. patients will be followed up to live birth. frozen/thawed embryo transfers (fet) will be performed until at least one live birth (≥20 weeks of gestation) occurred or all embryos resulting from the mentioned assisted ovarian stimulation were used.

Eligibility criteria:
inclusion criteria: * tubal factor infertility diagnosed by laparoscopy; * female age between 20-41 years; * bmi 17,5-35 kg/m2; * early follicular phase follicle stimulating hormone (fsh) ≤15 iu/l * presence of viable spermatozoa in partner's sperm; * signed informed consent. exclusion criteria: * previous ovarian surgery; * endometriosis; * antimullerian hormone (amh) level ≤0,3 ng/ml; * hyper- or hypogonadotropic ovarian failure; * severe male factor infertility; * pre-existing medical condition preventing or interfering with ivf treatment: any clinically significant systemic disease; inherited or acquires thrombophilia and thromboembolism; endocrine or metabolic abnormalities; moderate or severe impairment of renal or hepatic function; any oncological diseases in anamnesis; known history of recurrent miscarriage, abnormal karyotype of both partners; currently active pelvic inflammatory disease; * abnormal ivf screening tests: papanicolaou (pap) smear, syphilis, hiv 1\&2, hepatitis b, hepatitis c, chlamydia, and gonorrhea; * presence of uterine pathology: asherman's syndrome, endometrial polyps, nodus form of adenomyosis or uterine fibroids ≥3 mm in diameter; * visualization of ovarian cysts ≥25 mm, endometriomas or hydrosalpinx; * one or more follicles ≥8 mm at the start of the cos protocol.

Keywords: antichlamydial antibodies in vitro fertilization ovarian stimulation tubal factor infertility
prone positioning short-term effects on tissue oxygen saturation in critical covid-19 patients

Conditions: Covid19; ARDS, Human

Summary: the purpose of this study is to monitor short-term changes in tissue oxygen saturation and local blood flow as results of changing from supine to prone position in ards covid-19 patients

after obtaining consent to participate in the study, the subjects included in the study will undergo a baseline 15-minute measurement of tissue oxygen saturation (sto2) measured non-invasively on the forearm by means of near-infrared spectroscopy (nirs). once a baseline stable sto2 value is obtained, a provocative test, consisting of a transient vascular occlusion, will be performed. the test will allow the obtention of a local metabolic rate, and a sto2 recovery rate after the ischemic stimulus. tissue oxygenation measurements will be performed in supine position, immediately before changing to prone positioning, and repeated after 20 minutes of stabilization, once in prone position.

Eligibility criteria:
inclusion criteria: * covid-19 patients admitted in the icu receiving invasive mechanical ventilation and requiring prone positioning for severe hypoxemia management, as decided by the medical team exclusion criteria: * severe peripheral vasculopathy * raynaud's syndrome * skin lesions/trauma in upper limbs interfering the placement of the nirs probe and/or the occlusion tourniquet * deep venous thrombosis in the upper limbs

Keywords: covid-19 tissue oxygenation ards prone position
hypoxia blood validation in multiple pulse oximeters

Conditions: Hypoxia

Summary: the purpose of this study is to evaluate the spo2 accuracy and performance of multiple pulse oximeters during non-motion conditions over the range of 70-100% sao2 as compared to arterial blood samples assessed by co-oximetry for spo2 validation. this study is observational in nature which quantifies device performance and accuracy in comparison to a reference standard.

the purpose of this study is to evaluate the spo2 accuracy and performance of pulse oximeters during non-motion conditions over the range of 70-100% sao2 as compared to arterial blood samples assessed by co-oximetry for spo2 validation. the end goal is to show the spo2 accuracy performance of the pulse oximeters. it is expected that the accuracy root mean square (arms) performance of pulse oximeters will meet a specification of 3 or better in non-motion conditions for the range of 70-100% sao2 thereby demonstrating an acceptable spo2 accuracy performance specification

Eligibility criteria:
inclusion criteria: * healthy individuals between the age of 18-50 years. exclusion criteria: * clotting disorders, diabetes, currently taking psychotropic medications.

Keywords: pulse oximetry temperature respiratory rate respiratory gases this study determine the measurement accuracy of the physiological parameters
the effect of universal salt iodization on thyroid diseases

Conditions: Thyroid Nodule

Summary: 1. acquire the environmental iodine status of hangzhou 2. acquire the iodine status of population in hangzhou 3. acquire the prevalence of thyroid diseases in hangzhou 4. explore the association between iodized salt and thyroid disease


Eligibility criteria:
inclusion criteria: 1. age ≥ 6 years old; 2. living for above 5 years at present residence. exclusion criteria: 1. resident with coronary angiography (cag) or endoscopic retrograde cholangiopancreatography (ercp) in 6 months; 2. resident taking amiodarone drug; 3. resident with abnormal kidney function or serious illness
liraglutide in the prevention of type 2 diabetes after gestational diabetes

Conditions: Gestational Diabetes

Summary: obese women with history of gestational diabetes are in great danger to develop type 2 diabetes (t2d) within 5-10 years after delivery. aim of the study is to investigate if 12 months' liraglutide treatment could decrease the risk of t2d in obese women who have had gestational diabetes. the women are randomized either to liraglutide (victoza ® 1.8 mg) or placebo group, once daily. same laboratory tests are taken and instructions given at baseline 6 month and one year. after one year visits once a year until 5 years with same laboratory tests and measurements are taken.

incidence of type 2 diabetes (t2d) is increasing along with pandemia of obesity. gestational diabetes is the major risk factor for t2d in women and more than every tenth will develop gestational diabetes during pregnancy. t2d can be prevented by weight loss. health care professionals should take advantage of this opportunity to prevent this devastating disease in women. aim of the study is to investigate if 12 months' liraglutide treatment (1.8 mg) once daily could decrease the risk of t2d in obese women who have had gestational diabetes needing treatment with metformin and/or insulin. 100 women, who have had gestational diabetes with treatment with metformin and/or insulin and who have stopped lactation and are not pregnant are enrolled between 6 to 18 months after delivery. bmi should be ≥30 kg/m2. the women are randomized either to liraglutide (victoza ® 1.8 mg) or placebo group. both treatments are given by similar device s.c. once daily during 365 days. before starting the treatment, clinical examination and laboratory test are done. similar dietary instructions are given. same laboratory tests are taken and instructions given at 6 months and at one year after baseline. additional follow-up call (ae reporting) is scheduled at 3 months and a drug dispensing visit at 9 months. after one year visits once a year until 5 years with same laboratory tests and measurements are taken. primary end-point is development of t2d (fasting p-glucose \>7 mmol/l and/ or 2 h \>11 mmol/l in oral glucose tolerance test 75g, and/or hba1c≥ 6.5 %) from year 1 to 5.

Eligibility criteria:
inclusion criteria: * history of gestational diabetes with treatment with metformin and/or insulin * delivery 6 to 18 months before screening * bmi ≥30 kg/m2 * use of contraceptives (iu-device or oral contraceptive) exclusion criteria: * lactation * pregnancy * type 1 or type 2 diabetes * use of antidepressives, statins or anti-hyperglycemic therapies * severe hepatic insufficiency * end stage renal disease * history of pancreatitis
prevention of dental implant diseases

Conditions: Peri-Implantitis

Summary: the aim of this study is to determine the effect of regular antibacterial photodynamic lumoral® treatment on gingival health and plaque volume, and anti-inflammatory effect of daily double light therapy on implant teeth. the study will use a medical device containing a light-activated lumorinse® mouthwash and a lumoral® light activator.

the hypothesis is that antibacterial photodynamic therapy improves tissue health by reducing inflammation without any side effect. study participants will be invited from a dental clinic in tampere, finland, from the patients of an oral hygienist's office. participants will be randomized to the treatment and control groups using the closed envelope method. participants in the treatment group will receive lumoral® treatment according to the manufacturer's protocol, once daily for 10 min for 15 days and then twice daily for 15 days.

Eligibility criteria:
inclusion criteria: * one or more dental implants * diagnosis of peri-implantitis * challenges in keeping high self-care oral care standards * over 25 years of age exclusion criteria: - any antibiotic medication within 6 months prior to study participation

Keywords: peri-implant disease ammp-8 antibacterial photodynamic therapy (abpt) oral hygiene